RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma
These shared and divergent modulations elucidate the molecular underpinnings of RVd and CyBorD efficacy and inform precision regimen selection.
Authors
- Merav Leiba (ORCID: https://orcid.org/0000-0002-3410-8496)
- Gábor Beke (ORCID: https://orcid.org/0000-0002-3385-1317)
- Ľuboš Drgoňa (ORCID: https://orcid.org/0000-0002-5089-3201)
- Efstathios Kastritis (ORCID: https://orcid.org/0000-0001-8191-5832)
- David M. Dorfman (ORCID: https://orcid.org/0000-0002-6244-8535)
- Zuzana Valuskova
- Kenneth Carl Anderson (ORCID: https://orcid.org/0000-0002-6418-0886)
- Dana Cholujová (ORCID: https://orcid.org/0000-0003-4024-7713)
- Jana Jakubı́ková (ORCID: https://orcid.org/0000-0003-2593-569X)
- Milan Hucko
- Katarina Suroviakova
- Maria Elisabeth Marinkovicova
Institutions
- Ben-Gurion University of the Negev (IL)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- National and Kapodistrian University of Athens (GR)
- Slovak Academy of Sciences (SK)
- Dana-Farber Cancer Institute (US)
- Centre for Advanced Material Application of the Slovak Academy of Sciences (SK)
- Biomedical Research Center of the Slovak Academy of Sciences (SK)
- Comenius University Bratislava (SK)
Publication Details
- Journal
- Cancer Biology & Therapy
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1080/15384047.2025.2603100
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00